Survival of heparins, oral anticoagulants, and aspirin after the year 2010

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 1, 2008, Pages 58-73

  Fareed, Jawed ^a   Hoppensteadt, Debra A ^a   Fareed, Daniel ^b   Demir, Muzaffer ^b   Wahi, Rakesh ^c   Clarke, Melaine ^a   Adiguzel, Cafer ^a   Bick, Rodger ^d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b TRAKYA UNIVERSITY   (Turkey)

^c Grant Memorial Hospital   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anti Xa agents; Antithrombins; Aspirin; Heparin; Warfarin

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BEMIPARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CANGRELOR; CLOPIDOGREL; CYCLOOXYGENASE 1; DALTEPARIN; DU 176B; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HEPARIN COFACTOR II; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; PRASUGREL; PRT 054021; PURINERGIC P2Y12 RECEPTOR; RIVAROXABAN; SERINE PROTEINASE INHIBITOR; THROMBIN INHIBITOR; TICAGRELOR; TICLOPIDINE; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ANAPHYLAXIS; BLEEDING; CARDIOVASCULAR DISEASE; CATHETER THROMBOSIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG INHIBITION; DRUG SUBSTITUTION; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GRANULOCYTOPENIA; HEMOSTASIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; METABOLIC ACTIVATION; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIDE EFFECT; SURVIVAL; THROMBOCYTOPENIA; THROMBOSIS; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ASPIRIN; DRUG DESIGN; FACTOR XA; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLATELET AGGREGATION INHIBITORS; SAFETY; THROMBIN; THROMBOSIS; WARFARIN;

EID: 43149107206     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-2008-1066025     Document Type: Review

References (39)

1. Fareed J, Hoppensteadt DA, Bick RL. Management of thrombotic and cardiovascular disorders in the new millennium. Clin Appl Thromb Hemost 2003;9:101-108
2. Fareed J, Hoppensteadt DA. The management of thrombotic and cardiovascular disorders in the 21st century. In: Sasahara AA, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. 2nd ed. New York, NY: Marcel Dekker; 2002:687-693
3. Eikelboom JW, Weitz JI. A replacement for warfarin: the search continues. Circulation 2007;116:131-133
4. Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol 2006;134:3-19
5. Laux V, Hinder M. Rationale for direct factor Xa inhibitors in acute coronary syndromes. In: Kipshidze N, Fareed J, Moses JW, Serruys PW, eds. Textbook of International Cardiovascular Pharmacology. Andover, UK: Informa Healthcare; 2007: 119-126
6. Leong W, Hoppensteadt DA. Generic forms of low molecular weight heparins: some practical considerations. Clin Appl Thromb Hemost 2003;9:293-297
7. Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003;41:394-402
8. Fox KA. Implications of the organization to assess strategies for ischemic syndromes-2 (OASIS-2) study and the results in the context of other trials. Am J Cardiol 1999;84:26M-31M
9. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153
10. Linkins LA, Weitz JI. Pharmacology and clinical potential of direct thrombin inhibitors. Curr Pharm Des 2005;11:3877-3884
11. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibitors in myocardial infarction (TIMI) 9B trial. Circulation 1996;94:911-921
12. Cho L, Bhatt DL, Marso SP, et al. An invasive strategy is associated with decreased mortality in patients with acute coronary syndrome and non-ST elevation myocardial infarction: GUSTO IIb trial. Am J Med 2003;114:106-111
13. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997;79:326-333
14. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. a comparison of recombinant hirudin with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-1335
15. Lincoff AM, Bittl JA, Harrington RAet al. for the REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. JAMA 2003;289:853-863
16. Stone GW, McLaurin BT, Cox DAet al. for the ACUITY investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216
17. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs. deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 2007;297:591-602
18. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-919
19. Eichler P, Lubenow N, Strobel U, Greinacher A. Antibodies against lepirudin are polyspecifc and recognize epitopes on bivalirudin. Blood 2004;103:613-616
20. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843
21. Lewis BE, Wallis DE, Leya F, et al. Argatroban anti-coagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-1856
22. Dahl OE, Eriksson BI, Agnelli G, et al. Postoperative melagatran/ximelagatran for the prevention of venous thromboembolism following major elective orthopedic surgery: effects of timing of finishing factors for thromboembolism and bleeding complications on efficacy and safety. Clin Drug Investig 2005;25:65-77
23. Kalus JS, Caron MF. Novel uses for current and future direct thrombin inhibitors; focus on ximelagatran and bivalirudin. Expert Opin Investig Drugs 2004;13:465-477
24. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005;3: 2479-2486
25. Erikkson BI, Bonis L, Dahl O, et al. Oral, direct factor Xa inhibition with Bay 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4:121-128
26. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-1530
27. Saiah E, Soares C. Small molecule coagulation inhibitors in the clinic. Curr Trends Med Chem 2005;5:1677-1695
28. Aherns I, Smith BK, Bode C, Peter K. Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology. Expert Opin Drug Metab Toxicol 2007;3:609-620
29. Lewis BE, Matthai WH Jr, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced- thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177-184
30. Alexander JH, Yang H, Becker RC, et al. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the Xa NADV-ACS trial. J Thromb Haemost 2005;3: 439-447
31. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 2007;115:2642-2651
32. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-1339
33. Smith SC, Feldman TE, Hirschfeld JW, Jacobs AK. American College of Cardiology/American Heart Association Task Force on practice guidelines. ACC/AHA/SCA 2005. Circulation 2006;113:e166-e186
34. Bhatt DL, Bertrand ME, Berger PB. Meta-analysis of randomized and registry comparison of ticlopidine with Clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14
35. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1313
36. Hirsh J, Guyatt GH, Albers GW, Schunemann HJ. The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: evidence-based guidelines. Chest 2004;126:163S-703S
37. Fareed J. Anticoagulant management of patients undergoing interventional procedures. In: Kipshidze N, Fareed J, Moses JW, Serruys PW, eds. Textbook of International Cardiovascular Pharmacology. Andover, UK: Informa Healthcare; 2007:613-619
38. Flaker GC, Gruber M, Connolly SJ, et al. SPORTIF Investigators. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006;152:967-973
39. Peterson P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation. SPORTIF II: a dose guiding tolerability and safety study. J Am Coll Cardiol 2003;41: 1445-1451